<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>Special Clinical Situations</title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>
<body>

<div class="uk-container">
    <div>
        <div class="chapter-header">
            <div class="header-title">
                <div>
                    <img src="ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                </div>
                <p class="chapter-title">Special Clinical Situations</p>
            </div>
            <p class="last-updated"><i>Last Updated June 2024</i></p>
        </div>
        <hr>
    </div>
    <ol>
        <li>
            <p>Dosing for TB medications in adults with renal impairment is shown in <a href="table_13_antituberculosis_antibiotics_in_adult_patients_with_renal_impairment.html">Table 13 </a>.</p>
        </li>

        <li><p>Therapy for TB in clinical situations for which standard TB therapy may not be tolerated or may be
            ineffective is shown in <a href="table_14_antituberculosis_medications_which_may_be_used_for_patients_who_have_contraindications_to_or_intolerance.html">Table 14 </a> and <a href="table_15_clinical_situations_for_which_standard_therapy_cannot_be_given_or_is_not_well_tolerated.html"> Table 15 </a>.</p></li>
        <li>There is a new 4-month TB treatment regimen for the treatment of drug-susceptible active TB disease as noted above. At this time, the Georgia Department of Public Health does not have the infrastructure for routine implementation of this 4-month treatment regimen.</li>
        
            <li><b class="toggle-title" onclick="toggleItem(this)"><span>Current obstacles to implementation include:</span><span class="chevron-up">⌃</span></b>
            <div class="item">
                <ul>
                <li>Supply of Rifapentine (cost and access) </li>
                <li>Genotypic and phenotypic testing for fluoroquinolone (FQ) susceptibility (cost and access).</li></ul>
            </div>
            </li>


    </ol>

    <ul>
        <li><a href="#table7">Table 7. Treatment of Adults and Children with Drug Susceptible TB Pulmonary TB </a></li>
        <li><a href="#figure1">Figure 1. Factors to be considered in deciding to initiate treatment empirically for active TB</a></li>
        <li><a href="#table8">Table 8. First-Line TB Drugs: Dosing for Adults</a></li>
        <li><a href="#table9">Table 9. Pediatric Dosages - Isoniazid in Children</a></li>
        <li><a href="#table10">Table 10. Pediatric Dosages - Rifampin in Children</a></li>
        <li><a href="#table11">Table 11. Pediatric Dosages - Ethambutol in Children</a></li>
        <li><a href="#table12">Table 12. Pediatric Dosages - Pyrazinamide in Children</a></li>
        <li><a href="#table13">Table 13. Antituberculosis Antibiotics in Adult Patients with Renal Impairment</a></li>
        <li><a href="#table14">Table 14. Medications for patients with contraindications to or intolerance of first line agents or who require IV therapy during acute or critical illness</a></li>
        <li><a href="#table15">Table 15. Clinical Situations when standard therapy cannot be given or is not well-tolerated or may not be effective</a></li>
    </ul>

    <h4 id="table7" class="custom-table-title">Table 7: Recommended Regimens for Treatment of Adults and Children with Drug Susceptible TB Pulmonary TB</h4>
        <div class="uk-overflow-auto"
            id="table_7_recommended_regimens_for_treatment_of_adults_and_children_with_drug_susceptible_tb_pulmonary_tb">
            <div class="uk-tabs-container">
                <ul class="tabs">
                    <li><button class="tab-button active-option" onclick="switchTab(0, event)">Option 1</button></li>
                    <li><button class="tab-button" onclick="switchTab(1, event)">Option 2</button></li>
                </ul>
            </div>
    
            <div id="content0" class="option-content active-option">
                <span class="duration">Total Duration: 6^</span>
    
                <h3 class="highlight">Initial Phase</h3>
    
                <table class="uk-table uk-table-small">
                    <tbody>
                        <tr>
                            <th colspan="2">Drug</th>
                            <td colspan="2">Isoniazid Rifampin Pyrazinamide Ethambutol</td>
                        </tr>
                        <tr>
                            <th colspan="2">Interval & Dose # (minimal duration)</th>
                            <td colspan="2">Daily DOT for 40 doses (8 weeks)</td>
                        </tr>
                    </tbody>
                </table>
    
                <h3 class="highlight">Continuation Phase</h3>
    
                <table class="uk-table uk-table-small">
                    <tbody>
                        <tr>
                            <th colspan="2">Drug</th>
                            <td colspan="2">Isoniazid Rifampin Vitamin B6</td>
                            <td colspan="2">Isoniazid Rifampin</td>
                        </tr>
                        <tr>
                            <th colspan="2" class="uk-table-expand">Interval & Dose # (minimal duration)</th>
                            <td colspan="2">1a. Daily DOT for 90 doses (18 weeks)</td>
                            <td colspan="2">1b. Thrice weekly DOT for 54 doses (18 weeks)</td>
                        </tr>
                        <tr>
                            <th rowspan="2" class="uk-table-expand">Comments</th>
                            <td colspan="2">Regimen must given by DOT.</td>
                            <td colspan="2">Continue ethambutol until susceptibility to isoniazid and rifampin is demonstrated</td>
                        </tr>
                    </tbody>
                </table>
            </div>
    
            <div id="content1" class="option-content">
                <span class="duration">Total Duration: 6^</span>
    
                <h3 class="highlight">Initial Phase</h3>
    
                <table class="uk-table uk-table-small">
                    <tbody>
                        <tr>
                            <th colspan="2">Drug</th>
                            <td colspan="2">Isoniazid Rifampin Pyrazinamide Ethambutol Vitamin B6</td>
                        </tr>
                        <tr>
                            <th colspan="2">Interval & Dose # (minimal duration)</th>
                            <td colspan="2">Daily DOT for 10 doses (2 weeks) then twise weekly DOT for 12 doses (6 weeks)</td>
                        </tr>
                    </tbody>
                </table>
    
                <h3 class="highlight">Continuation Phase</h3>
    
                <table class="uk-table uk-table-small">
                    <tbody>
                        <tr>
                            <th class="uk-table-expand">Drug</th>
                            <td>Isoniazid Rifampin Vitamin B6</td>
                        </tr>
                        <tr>
                            <th class="uk-table-expand">Interval & Dose # (minimal duration)</th>
                            <td>2a. Twise weekly DOT for 36 doses (18 weeks)</td>
                        </tr>
                        <tr>
                            <th class="uk-table-expand">Comments</th>
                            <td>We do not recommend this regimen. If used, it must be given by DOT. Include ethambutol in the initial phase. After the initial phase, continue ethambutol until susceptibility to INH and rigampin is demonstrated</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <p>Table 7 Notes</p>
            <p>NOTE: 1 Daily DOT = 5 days/week (Monday through Friday). Self administered doses (including those on
                weekends) will not be counted toward the total doses.</p>
            <p>NOTE 2: Regimen 1a is the preferred regimen for patients with newly diagnosed TB.</p>
            <p>NOTE 3: Pyridoxine (Vitamin B6) 25 - 50 mg/daily should be added to all regimens that include isoniazid
                (INH) in adults to prevent development of INH- induced peripheral neuropathy. For patients with pre-existing
                peripheral neuropathy, increase pyridoxine dose to 100 mg/day unless there is abnormal renal function.</p>
            <p>^NOTE: Duration of therapy for patients with drug-susceptible TB should be extended to 9 months (31 weeks
                continuation phase, 39 weeks total) for patients who have cavitary pulmonary TB and remain sputum culture
                positive after 2 months of therapy. Many experts would extend therapy to 9 months for all patients with
                HIV/TB, especially those slow to convert to negative cultures or not on effective HIV treatment.</p>
            <p>*NOTE: Option 2 should NOT be used for patients living with HIV, cavitary pulmonary TB, disseminated TB, vertebral TB or for patients who have co-morbid medical conditions such as diabetes mellitus, end- stage renal disease or liver disease.</p>
            <p>NOTE: Split dosing should be avoided.</p>
            <p>NOTE: Refer to current drug reference or drug package insert for a complete
                list of adverse drug reactions and drug interaction.</p>
        </div>
        
    <h4 id="figure1">Figure 1. Factors to be considered in deciding to initiate treatment empirically for active tuberculosis (TB) (prior
        to microbiologic confirmation)</h4>
    <div class= "uk-container">


        <img alt="Figure 1" src="figure1.png" style='height: 100%; width: 100%; object-fit: contain'>

        <p>Abbreviations: AFB, acid-fast bacilli; HIV, human immunodeficiency virus; IGRA, interferon-γ release assay; Mtb,
            Mycobacterium tuberculosis; TNF, tumor necrosis factor; TST, tuberculin skin test.</p>
        <p>Clin Infect Dis, Volume 63, Issue 7, 1 October 2016, Pages 853–867, <a href=https://doi.org/10.1093/cid/ciw566>https://doi.org/10.1093/cid/ciw566</a>
        </p>

        <p>Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author
            2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For
            permissions, email journals.permissions@oup.com.</p>

    </div>


    <h4 id="table8" class="custom-table-title">Table 8: First-Line TB Drugs: Fixed/ Weight Based Dose for Adults (ages 16 and over) Directly Observed Therapy (DOT) is mandatory</h4>
    <div class="uk-container">
        <div class="uk-overflow-auto"
                id="table_8_first-line_tb_drugs_dosing_for_adults_(ages_16_and_over)_directly_observed_therapy_(dot)_is_mandatory">
                <div class="uk-tabs-container">
                    <ul class="tabs">
                        <li><button class="tab-button active-option" onclick="switchTab(2, event)"> Isoniazid</button></li>
                        <li><button class="tab-button" onclick="switchTab(3, event)"> Rifampin</button></li>
                        <li><button class="tab-button" onclick="switchTab(4, event)"> Rifabutin</button></li>
                        <li><button class="tab-button" onclick="switchTab(5, event)"> Pyrazinamide**</button></li>
                        <li><button class="tab-button" onclick="switchTab(6, event)"> Ethambutol**</button></li>
                    </ul>
                </div>
        
                <div id="content2" class="option-content active-option">
                    <table class="uk-table uk-table-small uk-table-divider">
                        <tbody>
                            <tr>
                                <th class="uk-table-shrink">Frequency</th>
                                <td>Daily</td>
                                <td>Thrice-Weekly</td>
                            </tr>
                            <tr>
                                <th class="uk-table-shrink">Adult Dose based on body weight in kilograms (kg)*</th>
                                <td>300 mg</td>
                                <td>900 mg</td>
                            </tr>
                            <tr>
                                <th class="uk-table-shrink">Adverse Reactions</th>
                                <td colspan="2">
                                    <ul>
                                        <li>Gastrointestinal (GI) upset</li>
                                        <li>Liver enzyme elevation</li>
                                        <li>Hepatitis</li>
                                        <li>Mild effects on central nervous</li>
                                        <li>Drug interactions</li>
                                    </ul>
                                </td>
                            </tr>
                        </tbody>
                    </table>
                </div>
        
                <div id="content3" class="option-content">
                    <table class="uk-table uk-table-small uk-table-divider">
                        <tbody>
                            <tr>
                                <th class="uk-table-shrink">Frequency</th>
                                <td>Daily</td>
                                <td>Thrice-Weekly</td>
                            </tr>
                            <tr>
                                <th class="uk-table-shrink">Adult Dose based on body weight in kilograms (kg)*</th>
                                <td>600 mg</td>
                                <td>600 mg</td>
                            </tr>
                            <tr>
                                <th class="uk-table-shrink">Adverse Reactions</th>
                                <td colspan="2">
                                    <ul>
                                        <li>Orange discoloration of body fluids and secretions</li>
                                        <li>Drug interactions</li>
                                        <li>GI upset</li>
                                        <li>Hepatitis</li>
                                        <li>Bleeding problems</li>
                                        <li>Influenze-like symptoms</li>
                                        <li>Rash</li>
                                        <li>Uveitis (rifabutin only)</li>
                                    </ul>
                                </td>
                            </tr>
                        </tbody>
                    </table>
                </div>
        
                <div id="content4" class="option-content">
                    <table class="uk-table uk-table-small uk-table-divider">
                        <tbody>
                            <tr>
                                <th class="uk-table-shrink">Frequency</th>
                                <td>Daily</td>
                                <td>Thrice-Weekly</td>
                            </tr>
                            <tr>
                                <th class="uk-table-shrink">Adult Dose based on body weight in kilograms (kg)*</th>
                                <td>300 mg</td>
                                <td>Not recommended</td>
                            </tr>
                            <tr>
                                <th class="uk-table-shrink">Adverse Reactions</th>
                                <td colspan="2">
                                    <ul>
                                        <li>Orange discoloration of body fluids and secretions</li>
                                        <li>Drug interactions</li>
                                        <li>GI upset</li>
                                        <li>Hepatitis</li>
                                        <li>Bleeding problems</li>
                                        <li>Influenze-like symptoms</li>
                                        <li>Rash</li>
                                        <li>Uveitis (rifabutin only)</li>
                                    </ul>
                                </td>
                            </tr>
                        </tbody>
                    </table>
                </div>
        
                <div id="content5" class="option-content">
                    <table class="uk-table uk-table-small uk-table-divider">
                        <tbody>
                            <tr>
                                <th class="uk-table-shrink">Frequency</th>
                                <td>Daily</td>
                                <td>Thrice-Weekly</td>
                            </tr>
                            <tr>
                                <th rowspan="3" class="uk-table-shrink">Adult Dose based on body weight in kilograms (kg)*</th>
                                <td>40-55 kg: 1000 mg</td>
                                <td>40-55 kg: 1500 mg</td>
                                <tr>
                                    <td>56-75 kg: 2500 mg</td>
                                    <td>56-75 kg: 1500 mg</td>
                                </tr>
                                <tr>
                                    <td>76+ kg: 3000 mg</td>
                                    <td>76+ kg: 4000 mg</td>
                                </tr>
                            </tr>
                            <tr>
                                <th class="uk-table-shrink">Adverse Reactions</th>
                                <td colspan="2">
                                    <ul>
                                        <li>Orange discoloration of body fluids and secretions</li>
                                        <li>Drug interactions</li>
                                        <li>GI upset</li>
                                        <li>Hepatitis</li>
                                        <li>Bleeding problems</li>
                                        <li>Influenze-like symptoms</li>
                                        <li>Rash</li>
                                        <li>Uveitis (rifabutin only)</li>
                                    </ul>
                                </td>
                            </tr>
                        </tbody>
                    </table>
                </div>
        
                <div id="content6" class="option-content">
                    <table class="uk-table uk-table-small uk-table-divider">
                        <tbody>
                            <tr>
                                <th class="uk-table-shrink">Frequency</th>
                                <td>Daily</td>
                                <td>Thrice-Weekly</td>
                            </tr>
                            <tr>
                                <th rowspan="3" class="uk-table-shrink">Adult Dose based on body weight in kilograms (kg)*</th>
                                <td>40-55 kg: 800 mg</td>
                                <td>40-55 kg: 1200 mg</td>
                                <tr>
                                    <td>56-75 kg: 1200 mg</td>
                                    <td>56-75 kg: 2000 mg</td>
                                </tr>
                                <tr>
                                    <td>76+ kg: 1600 mg</td>
                                    <td>76+ kg: 2400 mg</td>
                                </tr>
                            </tr>
                            <tr>
                                <th class="uk-table-shrink">Adverse Reactions</th>
                                <td colspan="2">
                                    <ul>
                                        <li>Optic neuritis</li>
                                    </ul>
                                </td>
                            </tr>
                        </tbody>
                    </table>
                </div>

            <p>*Formula used to convert pounds to kilograms: Divide pounds by 2.2 to get kilograms.</p>
            <p>Example: Patient weighs 154 pounds ÷ 2.2 = 70 kilograms.</p>
            <p>** Calculate pyrazinamide and ethambutol doses using actual body weight. Pyrazinamide and ethambutol dosage
                adjustment is needed in patients with estimated creatinine clearance less than 50 ml/min or those with
                end-stage renal disease on dialysis.</p>
            <p>NOTE: Refer to current drug reference or drug package insert for a complete list of adverse drug reactions
                and drug interactions.</p>


        </div>
    </div>

    <h4 id="table9" class="custom-table-title">Table 9: Pediatric Dosage - Isoniazid in Children (birth to 15 years)</h4>

    <div class="uk-container">
        
        <div class="uk-overflow-auto"
                id="table_9_pediatric_dosage_isoniazid_in_children_(birth_to_15_years)">
            <table class="uk-table uk-table-small uk-table-divider">
                <thead>
                <tr>
                    <th class="uk-table-expand">Child's Weight (lbs)</th>
                    <th class="uk-table-expand">Child's Weight (kg)</th>
                    <th class="uk-table-expand">Daily Dose (mg) 10-15 mg/kg PO</th>
                    <!-- <th class="uk-table-expand">Twice-weekly Dose (mg) 20-30 mg/kg PO</th> -->
                </tr>
                </thead>
                <tr>
                    <td>6 - 10</td>
                    <td>3 - 4.5</td>
                    <td>50</td>
                    <!-- <td>100mg PO</td> -->
                </tr>
                <tr>
                    <td>11 - 14</td>
                    <td>5.0 - 6.0</td>
                    <td>50</td>
                    <!-- <td>150mg PO</td> -->
                </tr>
                <tr>
                    <td>14.5 - 18</td>
                    <td>6.5 – 8.0</td>
                    <td>100</td>
                    <!-- <td>200mg PO</td> -->
                </tr>
                <tr>
                    <td>18.5 - 21.5</td>
                    <td>8.5 – 9.5</td>
                    <td>100</td>
                    <!-- <td>250mg PO</td> -->
                </tr>
                <tr>
                    <td>22 – 24</td>
                    <td>10.0 – 11</td>
                    <td>150</td>
                    <!-- <td>300mg PO</td> -->
                </tr>
                <tr>
                    <td>25 - 29</td>
                    <td>11.5 - 13</td>
                    <td>150</td>
                    <!-- <td>350 mg PO</td> -->
                </tr>
                <tr>
                    <td>29.5 - 32</td>
                    <td>13.5 - 14.5</td>
                    <td>200</td>
                    <!-- <td>400 mg PO</td> -->
                </tr>
                <tr>
                    <td>33 - 35</td>
                    <td>15 - 16</td>
                    <td>200</td>
                    <!-- <td>450 mg PO</td> -->
                </tr>
                <tr>
                    <td>36 - 40</td>
                    <td>16.5 - 18</td>
                    <td>250</td>
                    <!-- <td>500 mg PO</td> -->
                </tr>
                <tr>
                    <td>40.5 - 43</td>
                    <td>18.5 - 19.5</td>
                    <td>250</td>
                    <!-- <td>550 mg PO</td> -->
                </tr>
                <tr>
                    <td>44 - 48</td>
                    <td>20 - 21.5</td>
                    <td>300</td>
                    <!-- <td>600 mg PO</td> -->
                </tr>
                <tr>
                    <td>48.5 - 51</td>
                    <td>22 - 23</td>
                    <td>300</td>
                    <!-- <td>650 mg PO</td> -->
                </tr>
                <tr>
                    <td>52 - 54.5</td>
                    <td>23.5 - 24.5</td>
                    <td>300</td>
                    <!-- <td>700 mg PO</td> -->
                </tr>
                <tr>
                    <td>55 - 57.5</td>
                    <td>25 - 26</td>
                    <td>300</td>
                    <!-- <td>750 mg PO</td> -->
                </tr>
                <tr>
                    <td>58 - 62</td>
                    <td>26.5 - 28</td>
                    <td>300</td>
                    <!-- <td>800 mg PO</td> -->
                </tr>
                <tr>
                    <td>62.5 - 65</td>
                    <td>28.5 - 29.5</td>
                    <td>300</td>
                    <!-- <td>850 mg PO</td> -->
                </tr>
                <tr>
                    <td>66 +</td>
                    <td>30 +</td>
                    <td>300</td>
                    <!-- <td>900 mg PO</td> -->
                </tr>
            </table>

            <p>NOTE: Isoniazid tablets come in 50 mg, 100mg, 300 mg sizes and can be crushed for oral administration.
                Isoniazid tablets are also scored.</p>
            <p>Isoniazid Syrup (50mg/5ml) should not be refrigerated. It contains sorbitol and will cause diarrhea. It
                should be used only when crushed tablets cannot accommodate the situation. (keep at room temperature).</p>

        </div>
    </div>


    <h4 id="table10" class="custom-table-title">Table 10. Pediatric Dosages - Rifampin in Children (birth to 15 years)</h4>
    <div class="uk-container">  
        <div class="uk-overflow-auto"
                id="table_10_pediatric_dosages_rifampin_in_children_(birth_to_15_years)">
            <table class="uk-table uk-table-small uk-table-divider">
                <thead>
                    <tr>
                        <th class="uk-table-expand">Child's Weight (lbs)</th>
                        <th class="uk-table-expand">Child's Weight (kg)</th>
                        <th class="uk-table-expand">Dose (mg) 10-20 mg/kg</th>
                        
                    </tr>
                    </thead>
                    <tr>
                        <td>15 - 32</td>
                        <td>7 - 14.5</td>
                        <td>150 mg</td>
                    </tr>
                    <tr>
                        <td>33 - 48.5</td>
                        <td>15 - 22</td>
                        <td>300 mg</td>
                    </tr>
                    <tr>
                        <td>49 - 65</td>
                        <td>22.5 - 29.5</td>
                        <td>450 mg</td>
                    </tr>
                    <tr>
                        <td>66 +</td>
                        <td>30 +</td>
                        <td>600 mg</td>
                    </tr>
            </table>
        </div>
    </div>


    <h4 id="table11" class="custom-table-title">Table 11: Pediatric Dosages - Ethambutol in Children (birth to 15 years)</h4>
    <div class="uk-container">
        <div class="uk-overflow-auto"
                id="table_11_pediatric_dosages_ethambutol_in_children_(birth_to_15_years)">
            <table class="uk-table uk-table-small uk-table-divider">
                <thead>
                <tr>
                    <th>Child’s Weight (lbs)</th>
                    <th>Child’s Weight (kg)</th>
                    <th>Daily Dose (mg) 15 – 25 mg/kg</th>
                </tr>
                </thead>
                <tr>
                    <td>11 – 15</td>
                    <td>5 – 7</td>
                    <td>100 mg</td>
                </tr>
                <tr>
                    <td>16 – 31</td>
                    <td>8 – 14</td>
                    <td>200 mg</td>
                </tr>
                <tr>
                    <td>32 – 44</td>
                    <td>15 – 20</td>
                    <td>300 mg</td>
                </tr>
                <tr>
                    <td>45 – 55</td>
                    <td>21 – 25</td>
                    <td>400 mg</td>
                </tr>
                <tr>
                    <td>56 – 67</td>
                    <td>26 – 30.5</td>
                    <td>500 mg</td>
                </tr>
                <tr>
                    <td>68 – 76</td>
                    <td>31 – 34.5</td>
                    <td>600 mg</td>
                </tr>
                <tr>
                    <td>77 – 87</td>
                    <td>35 – 39.5</td>
                    <td>700 mg</td>
                </tr>
                <tr>
                    <td>88 – 121</td>
                    <td>40 – 55</td>
                    <td>800 mg</td>
                </tr>
                <tr>
                    <td>122 – 165</td>
                    <td>56 – 75</td>
                    <td>1200 mg</td>
                </tr>
                <tr>
                    <td>166 +</td>
                    <td>76 +</td>
                    <td>1600 mg</td>
                </tr>
            </table>
            <p>
                The maximum recommendation for ethambutol is 1 g daily.
            </p>
        </div>
    </div>


    <h4 id="table12" class="custom-table-title">Table 12: Pediatric Dosages - Pyrazinamide in Children (birth to 15 years)</h4>
    <div class="uk-container">
        
        <div class="uk-overflow-auto"
                id="table_12_pediatric_dosages_pyrazinamide_in_children_(birth_to_15_years)">
            <table class="uk-table uk-table-small uk-table-divider">
                <thead>
                <tr>
                    <th class="uk-table-expand">Child's Weight (lbs)</th>
                    <th class="uk-table-expand">Child's Weight (kg)</th>
                    <th class="uk-table-expand">Daily Dose (mg) 30-40 mg/kg PO</th>
                 
                </tr>
                </thead>
                <tr>
                    <td>13 - 23</td>
                    <td>6 - 10.5</td>
                    <td>250 mg</td>
                  
                </tr>
                <tr>
                    <td>24 - 26</td>
                    <td>11 - 12</td>
                    <td>250 mg</td>
                   
                </tr>
                <tr>
                    <td>27 - 31</td>
                    <td>12.5 - 14</td>
                    <td>500 mg</td>
                  
                </tr>
                <tr>
                    <td>32 - 41</td>
                    <td>14.5 - 18.5</td>
                    <td>500 mg</td>
                 
                </tr>
                <tr>
                    <td>42 - 47</td>
                    <td>19.0 - 21.5</td>
                    <td>750 mg</td>
                  
                </tr>
                <tr>
                    <td>48 - 54</td>
                    <td>22.0 - 24.5</td>
                    <td>750 mg</td>
                   
                </tr>
                <tr>
                    <td>55 – 63</td>
                    <td>25 – 28.5</td>
                    <td>1000 mg</td>
                 
                </tr>
                <tr>
                    <td>64 – 67</td>
                    <td>29 – 30.5</td>
                    <td>1000 mg</td>
                    
                </tr>
                <tr>
                    <td>68 – 80</td>
                    <td>31 – 36.5</td>
                    <td>1250 mg</td>
                    
                </tr>
                <tr>
                    <td>81 – 93</td>
                    <td>37 – 42.5</td>
                    <td>1500 mg</td>
                   
                </tr>
                <tr>
                    <td>94 – 106</td>
                    <td>43 – 48.5</td>
                    <td>1750 mg</td>
                 
                </tr>
                <tr>
                    <td>107 +</td>
                    <td>49 +</td>
                    <td>2000 mg</td>
                 
                </tr>
            </table>
        </div>
    </div>


    <h4 id="table13" class="custom-table-title">Table 13: Antituberculosis Antibiotics in Adult Patients with Renal Impairment</h4>
    <div class="uk-container">
        <p>NOTE: Drug adjustments are based on the creatinine clearance (CrCl) which can be estimated as follows:</p>
        <p>[(140-age in yrs)(Ideal body weight in kg) for men (x 0l85 for women)] / [(72) (serum creatinine, mg/dL)]</p>
        <p>Ideal body weight for men: 50 kg + 2.3 kg per inch over 5 feet</p>
        <p>Ideal body weight for women: 45.5 kg + 2.3 kg per inch over 5 feet</p>
        <div class="uk-overflow-auto"
                id="table_13_antituberculosis_antibiotics_in_adult_patients_with_renal_impairment">
                         <div class="uk-tabs-container">
            <ul class="tabs">
                <li><button class="tab-button active-option" onclick="switchTab(7, event)"> INH</button></li>
                <li><button class="tab-button" onclick="switchTab(8, event)"> Rifampin</button></li>
                <li><button class="tab-button" onclick="switchTab(9, event)"> Ethambutol</button></li>
                <li><button class="tab-button" onclick="switchTab(10, event)"> Pyrazinamide</button></li>
                <li><button class="tab-button" onclick="switchTab(11, event)"> Levofloxacin</button></li>
                <li><button class="tab-button" onclick="switchTab(12, event)"> Moxifloxacin</button></li>
                <li><button class="tab-button" onclick="switchTab(13, event)"> Amikacin</button></li>
                <li><button class="tab-button" onclick="switchTab(14, event)"> Linezolid</button></li>
            </ul>
        </div>

        <p>
            NOTE: Drug adjustments are based on the creatinine clearance (CrCl) which can be estimated as follows: <br>
            [(140-age in yrs)(Ideal body weight in kg) for men (x 0l85 for women)] / [(72) (serum creatinine, mg/dL)]
            Ideal body weight for men: 50 kg + 2.3 kg per inch over 5 feet
            Ideal body weight for women: 45.5 kg + 2.3 kg per inch over 5 feet
        </p>

        <div id="content0" class="option-content active-option">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    <tr>
                        <th>Usual Dose (UD) Normal Renal Function</th>
                        <td>300 mg/day</td>
                    </tr>
                    <tr>
                        <th>CrCl 30-90</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>CrCL <30 or Hemodialysis</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>Peritoneal Dialysis</th>
                        <td rowspan="8" class="th-no-highlight">Data currently are not available for patients receiving peritoneal dialysis. Until data
                            become available, begin with doses recommended for patients receiving hemodialysis and verify
                            adequacy of dosing using serum concentration monitoring.
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content1" class="option-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    <tr>
                        <th>Usual Dose (UD) Normal Renal Function</th>
                        <td>600 mg/day</td>
                    </tr>
                    <tr>
                        <th>CrCl 30-90</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>CrCL <30 or Hemodialysis</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>Peritoneal Dialysis</th>
                        <td rowspan="8" class="th-no-highlight">Data currently are not available for patients receiving peritoneal dialysis. Until data
                            become available, begin with doses recommended for patients receiving hemodialysis and verify
                            adequacy of dosing using serum concentration monitoring.
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content2" class="option-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    <tr>
                        <th>Usual Dose (UD) Normal Renal Function</th>
                        <td>15-25 mg/kg/day</td>
                    </tr>
                    <tr>
                        <th>CrCl 30-90</th>
                        <td>UD</td> 
                    </tr>
                    <tr>
                        <th>CrCL <30 or Hemodialysis</th>
                        <td>20-25 mg/kg/dose thrice weekly</td>
                    </tr>
                    <tr>
                        <th>Peritoneal Dialysis</th>
                        <td rowspan="8" class="th-no-highlight">Data currently are not available for patients receiving peritoneal dialysis. Until data
                            become available, begin with doses recommended for patients receiving hemodialysis and verify
                            adequacy of dosing using serum concentration monitoring.
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content3" class="option-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    <tr>
                        <th>Usual Dose (UD) Normal Renal Function</th>
                        <td>25 mg/kg d (max 2 gm/day)</td>
                    </tr>
                    <tr>
                        <th>CrCl 30-90</th>
                        <td>UD</td> 
                    </tr>
                    <tr>
                        <th>CrCL <30 or Hemodialysis</th>
                        <td>25-35 mg/kg/dose thrice weekly</td>
                    </tr>
                    <tr>
                        <th>Peritoneal Dialysis</th>
                        <td rowspan="8" class="th-no-highlight">Data currently are not available for patients receiving peritoneal dialysis. Until data
                            become available, begin with doses recommended for patients receiving hemodialysis and verify
                            adequacy of dosing using serum concentration monitoring.
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content4" class="option-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    <tr>
                        <th>Usual Dose (UD) Normal Renal Function</th>
                        <td>750 mg/day</td>
                    </tr>
                    <tr>
                        <th>CrCl 30-90</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>CrCL <30 or Hemodialysis</th>
                        <td>750-1000 mg/dose thrice weekly</td>
                    </tr>
                    <tr>
                        <th>Peritoneal Dialysis</th>
                        <td rowspan="8" class="th-no-highlight">Data currently are not available for patients receiving peritoneal dialysis. Until data
                            become available, begin with doses recommended for patients receiving hemodialysis and verify
                            adequacy of dosing using serum concentration monitoring.
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content5" class="option-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    <tr>
                        <th>Usual Dose (UD) Normal Renal Function</th>
                        <td>400 mg/day</td>
                    </tr>
                    <tr>
                        <th>CrCl 30-90</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>CrCL <30 or Hemodialysis</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>Peritoneal Dialysis</th>
                        <td rowspan="8" class="th-no-highlight">Data currently are not available for patients receiving peritoneal dialysis. Until data
                            become available, begin with doses recommended for patients receiving hemodialysis and verify
                            adequacy of dosing using serum concentration monitoring.
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content6" class="option-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    <tr>
                        <th>Usual Dose (UD) Normal Renal Function</th>
                        <td>15 mg/kg/daily or thrice weekly</td>
                    </tr>
                    <tr>
                        <th>CrCl 30-90</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>CrCL <30 or Hemodialysis</th>
                        <td>15 mg/kg/dose thrice weekly</td>
                    </tr>
                    <tr>
                        <th>Peritoneal Dialysis</th>
                        <td rowspan="8" class="th-no-highlight">Data currently are not available for patients receiving peritoneal dialysis. Until data
                            become available, begin with doses recommended for patients receiving hemodialysis and verify
                            adequacy of dosing using serum concentration monitoring.
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content7" class="option-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                    <tr>
                        <th>Usual Dose (UD) Normal Renal Function</th>
                        <td>600 mg/day</td>
                    </tr>
                    <tr>
                        <th>CrCl 30-90</th>
                        <td>UD</td>
                    </tr>
                    <tr>
                        <th>CrCL <30 or Hemodialysis</th>
                        <td>600 mg/dose thrice weekly</td>
                    </tr>
                    <tr>
                        <th>Peritoneal Dialysis</th>
                        <td rowspan="8" class="th-no-highlight">Data currently are not available for patients receiving peritoneal dialysis. Until data
                            become available, begin with doses recommended for patients receiving hemodialysis and verify
                            adequacy of dosing using serum concentration monitoring.
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>
            
            <ul class="uk-list uk-list-disc">
                <li>Standard doses are given unless there is intolerance.</li>
                <li>The medications should be given after hemodialysis on the day of hemodialysis.</li>
                <li>Monitoring of serum drug concentrations should be considered to ensure adequate drug absorption, without
                    excessive accumulation, and to assist in avoiding toxicity.
                </li>
                <li>In patients with 30–50 mL/min creatinine clearance, standard doses are used by experts, but measurement
                    of serum concentrations 2 and 6 hours after timed administration can be used to assist with optimizing
                    drug dosages.
                </li>
            </ul>
            <p><a href="https://academic.oup.com/cid/article/63/7/e147/2196792">Based on Nahid et al. Clin Infect Dis
                2016;63(7):e147–95, Table 11</a></p>
        </div>
    </div>


    <h4 id="table14" class="custom-table-title">Table 14: Antituberculosis medications which may be used for patients who have contraindications to or intolerance of first line agents or who require IV therapy during acute or critical illness</h4>
    <div class="uk-container">
        <div class="uk-overflow-auto"
                id="table_14_antituberculosis_medications_which_may_be_used_for_patients_who_have_contraindications_to_or_intolerance">

        <div class="uk-tabs-container">
            <ul class="tabs">
                <li><button class="tab-button active-option" onclick="switchTab(15, event)">Levofloxacin: PO/IV</button></li>

                <li>
                    <button class="tab-button" onclick="switchTab(16, event)">Moxifloxacin: PO/IV</button>
                </li>

                <li><button class="tab-button" onclick="switchTab(17, event)">Linezolid: PO/IV</button></li>

                <li><button class="tab-button" onclick="switchTab(18, event)">Amikacin: IV</button></li>
            </ul>
        </div>

        <div id="content2" class="option-content active-option">
            <table class="uk-table uk-table-small">
                <tbody>
                    <tr>
                        <th class="uk-table-expand">Dosing (A for adults, C for children)</th>
                        <td>
                            <strong>A:</strong> 750 mg daily <br>
                            <strong>C:</strong> 15 – 20 mg/kg daily <br>
                            <strong>Max dose:</strong> 750 mg
                        </td>
                    </tr>
                    <tr>
                        <th class="uk-table-expand">Adverse Reactions</th>
                        <td>
                            GI upset, dizziness, hypersensitivity, Headaches, QT prolongation, tendon rupture (rare), arthralgia, increased risk for aortic dissection/rupture, hypo/hyperglycemia
                        </td>
                    </tr>
                </tbody>
            </table>

            <p>
                Expert consultation is advised before use; agent is not approved for children less than 18 years of age. 
            </p>
        </div>

        <div id="content3" class="option-content">
            <table class="uk-table uk-table-small">
                <tbody>
                    <tr>
                        <th class="uk-table-expand">Dosing (A for adults, C for children)</th>
                        <td>
                            <strong>A:</strong> 10-15 mg/kg<br>
                            <strong>C:</strong> No established dose<br>
                            <strong>Max dose:</strong> 400 mg
                        </td>
                    </tr>
                    <tr>
                        <th class="uk-table-expand">Adverse Reactions</th>
                        <td>
                            GI upset, dizziness, hypersensitivity, Headaches, QT prolongation, tendon rupture (rare), arthralgia, increased risk for aortic dissection/rupture, hypo/hyperglycemia
                        </td>
                    </tr>
                </tbody>
            </table>
            
            <p>
                Expert consultation is advised before use; agent is not approved for children less than 18 years of age. 
            </p>
        </div>

        <div id="content4" class="option-content">
            <table class="uk-table uk-table-small">
                <tbody>
                    <tr>
                        <th>Dosing (A for adults, C for children)</th>
                        <td>
                            <strong>A:</strong> 600 mg (once daily) <br>
                            <strong>C:</strong> 
                            <strong>Children < 12 years:</strong>
                            <ul>
                                <li>5 – 10 kg: 15 mg/kg once daily</li>
                                <li>10 – 23 kg: 12 mg/kg once daily</li>
                                <li>>23 kg: 10 mg/kg once daily</li>
                            </ul>
                            <strong>Children ≥12 years:</strong>
                            <ul>
                                <li>10 mg/kg once daily</li>
                            </ul>
                            <strong>Max dose:</strong> 600 mg
                        </td>
                    </tr>
                    <tr>
                        <th>Adverse Reactions</th>
                        <td>
                            Myelosuppression, GI upset, optic and peripheral neuropathy (may be irreversible)
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div id="content5" class="option-content">
            <table class="uk-table uk-table-small">
                <tbody>
                    <tr>
                        <th>Dosing (A for adults, C for children)</th>
                        <td>
                            <strong>A:</strong> 10 to 15 mg/kg/day <br>
                            5-7 days per week or 3 times per week <br><br>
                            
                            <strong>C:</strong> 15 to 30 mg/kg/day (max dose 1 gram) <br>
                            5-7 days per week or 3 times per week
                        </td>
                    </tr>
                    <tr>
                        <th>Adverse Reactions</th>
                        <td>
                            Auditory, vestibular and renal toxicity
                        </td>
                    </tr>
                </tbody>
            </table>
        </div>
        </div>
    </div>

    <h4 id="table15" class="custom-table-title">Table 15: Clinical Situations for which standard therapy cannot be given or is not well- tolerated or may not be effective: Potential Alternative Regimens (Dosing and/or Drugs) </h4> 
    <div class="uk-container">
        <div class="uk-overflow-auto"
             id="table_15_clinical_situations_for_which_standard_therapy_cannot_be_given_or_is_not_well_tolerated">
            <table class="uk-table uk-table-small uk-table-divider">
                <caption></caption>
                <thead>
                <tr>
                    <th class="uk-text-nowrap">Clinical Situation</th>
                    <th class="uk-text-nowrap">Concerns Raised</th>
                    <th class="uk-table-expand">Regimen</th>
                    <th>Comments</th>
                </tr>
                </thead>
                <tbody>
                <tr>
                    <td>Critical illness requiring vasopressors</td>
                    <td>Poor gut medication absorption</td>
                    <td>IV rifampin ≥ 10 mg/kg daily
                        PO pyrazinamide UD
                        PO ethambutol UD
                        IV isoniazid UD<sup>2,3</sup>
                        IV levofloxacin or moxifloxacin UD 4
                        IV linezolid UD 5<sup>4</sup>
                        IV amikacin UD<sup>5</sup></td>
                    <td>Oral medications are generally poorly bioavailable among critically ill patients.<p>Patients
                        receiving sedation are unable to report isoniazid or linezolid-induced neuropathies nor
                        aminoglycoside- induced otovestibular toxicity</p></td>
                </tr>
                <tr>
                    <td>Proven or suspected meningeal TB</td>
                    <td>Rapidly progressive and often fatal. High plasma levels needed to achieve adequate CNS penetration.
                        High index of suspicion necessary; microbiological diagnostic tests have low yield.
                    </td>
                    <td>IV rifampin ≥ 10 mg/kg daily
                        PO or IV<sup>2</sup> 2 isoniazid UD
                        PO pyrazinamide UD
                        PO ethambutol UD (adults)
                        PO ethionamide (children)
                        <p>Consider adding IV levofloxacin or moxifloxacin UD in lieu of ethambutol</p></td>
                    <td>Rifampin has poor CNS penetration but is an essential drug for meningeal TB treatment. Isoniazid,
                        pyrazinamide, levofloxacin, and moxifloxacin have excellent CNS penetration.
                        <p>Ethambutol has poor CNS penetration. Early use of fluoroquinolones has been associated with
                            improved outcomes among patients with isoniazid-resistant meningeal TB</p>
                    </td>
                </tr>
                <tr>
                    <td>Patient age 75 years or greater<sup>6</sup></td>
                    <td>Increased risk for pyrazinamide-induced hepatotoxicity</td>
                    <td>Can consider rifampin, isoniazid, and ethambutol without pyrazinamide when drug-susceptibility is
                        known and/or patient has low burden of disease
                    </td>
                    <td>3-drug regimens may increase risk of failure or acquired drug-resistance.</td>
                </tr>
                <tr>
                    <td>Disseminated TB with concern for poor absorption from gut<sup>6</sup></td>
                    <td>Disseminated TB is associated with gut edema which decreases po medication bioavailability</td>
                    <td>Standard 4-drug regimen Consider increasing po Rifampin dose (15 to 20 mg/kg daily, minimum 600 mg)
                        Consider IV rifampin and IV isoniazid 1 for inpatients.
                    </td>
                    <td>Consider obtaining TB drug levels in ensure po dosing achieves at least minimum levels</td>
                </tr>
                <tr>
                    <td>Patient receiving medications via nasogastric or PEG tube<sup>6</sup></td>
                    <td>Tube feeds may decrease TB drug bioavailability</td>
                    <td>No change in standard TB regimen</td>
                    <td>Hold tube feeds ≤2 hours prior and ≥1 hour after TB drug intake. Longer intervals are needed if
                        quinolone- containing regimens are given with divalent-cationcontainingtubefeeds
                    </td>
                </tr>
                <tr>
                    <td>Baseline elevation of liver enzymes<sup>6</sup></td>
                    <td>Consider limiting number of hepatotoxic drugs for patients with baseline ALT>3x UNL and/or advanced
                        liver disease.
                        Order of hepatotoxicity: PZA>INH>RIF
                    </td>
                    <td>1-RIF/INH/EMB +/- FQN 2-RIF/EMB/FQN +/- LZD or AG 3-EMB/FQN +/- LZD or AG</td>
                    <td>Consider baseline liver enzyme elevation could be due to hepatic TB
                        <p>3-drug regimens may increase risk of failure or acquired drug-resistance.</p>
                    </td>
                </tr>
                <tr>
                    <td>Acute hepatitis after starting standard therapy<sup>6</sup></td>
                    <td>TB drug-induced hepatotoxicity
                        Stop TB drugs if ALT>3x UNL and patient symptomatic or ALT >5x UNL regardless of symptoms
                    </td>
                    <td>Sequential re-introduction of TB drugs once ALT <2x UNL.
                        (1) Rifamycin x 5-7 days
                        (2) Isoniazid x 5-7 days
                        (3) Ethambutol x 5-7 days
                        (4) Need and choice of 4th agent depends on burden of disease and drug-susceptibility pattern.
                    </td>
                    <td>Pyrazinamide is often the culprit and effective regimens can be designed without this drug.
                        Rifamycins are the drugs most important for sterilizing activity (i.e., cure) in TB treatment.
                        Consider adding a 4th drug if patient has high burden of disease.
                    </td>
                </tr>
    
                </tbody>
            </table>
            <p>Abbreviations: UD, usual dose; UNL, upper normal limit.</p>
            <p>TABLE 15 NOTES</p>
            <P>1-Some of these recommendations differ or are not addressed by 2016 ATS/CDC/IDSA drug-susceptible TB
                guidelines. Drug-susceptibility testing for second-line drugs should be requested if these agents are
                used.</P>
            <P>2-Limited availability</P>
            <p>3-Associated with peripheral neuropathy. Add B6 ≥50 mg/daily</p>
            <p>4-Associated with irreversible peripheral and optic neuritis. Add B6 ≥ 50 mg/daily</p>
            <p>5-Associated with otovestibular toxicity</p>
            <p>6-These recommendations are meant for patients with known drug-susceptible TB or at low risk for drug-
                resistant TB</p>
        </div>
    </div>

</div>
</body>
<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
<script src="main.js" type="text/javascript"></script>
</html>
